Key facts
- This page summarizes Arthur S. Kirsch's Form 3 filing for Atea Pharmaceuticals, Inc. (AVIR).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 Feb 2025, 18:47.
Arthur S. Kirsch - 20 Feb 2025 Form 3 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)
- Reporting relationship
- Director
- Issuer ticker
- AVIR
- Reported as of
- 20 Feb 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 24 Feb 2025, 18:47:18 UTC
- Prior SEC filing
- 24 Jun 2024
- Next SEC filing
- 20 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrea Corcoran, as Attorney-in-Fact for Arthur S. Kirsch
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Arthur S. Kirsch filed Form 3 for Atea Pharmaceuticals, Inc. (AVIR) on 24 Feb 2025.
Change
- Previous filing in this sequence was filed on 24 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVIR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 35,710
- Date
- 20 Feb 2025
- Ownership
- Direct
AVIR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,000
- Date
- 20 Feb 2025
- Ownership
- By trust
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit List: Exhibit 24 - Power of Attorney